Business Model Breakdown
How FMC Corp Makes Money
FMC
Market Cap
$1.7B
Annual Revenue
$3.6B
Profit Margin
-63.5%
Employees
5,700
The Short Version
FMC Corp is a global agricultural sciences company dedicated to helping farmers enhance crop yields and protect their produce. They achieve this by researching, developing, manufacturing, and marketing a diverse portfolio of crop protection chemicals, including insecticides, herbicides, and fungicides. Their business model relies on continuous innovation in chemical science, maintaining a robust patent portfolio, and leveraging a global distribution network to reach farmers who use their products to safeguard crops against pests, weeds, and diseases, thereby ensuring food security and agricultural productivity.
Where the Revenue Comes From
Sales of Insecticides (~35-45% of revenue - illustrative, not specified in data)
Sales of Herbicides (~30-40% of revenue - illustrative, not specified in data)
Sales of Fungicides and other crop protection products (~15-25% of revenue - illustrative, not specified in data)
Who buys: Farmers, growers, and agricultural businesses worldwide.
Why It Works (Competitive Advantages)
- ✔Established portfolio of crop protection products (herbicides, insecticides, fungicides)
- ✔Proprietary R&D and intellectual property in chemical formulations (e.g., Rimisoxafen classification)
- ✔Global distribution network and established customer relationships
Economic Moat: Narrow (Intangible Assets/IP (R&D, patents for chemical compounds), Switching Costs (for farmers integrated with specific product lines), Brand Power (established trust in the agricultural community))
What Our Analysis Says
DVR Score as of April 9, 2026
FMC Corporation operates in the mature and cyclical agricultural sciences industry, focusing on crop protection. The company's business model and market dynamics do not align with 10x growth potential within 3-5 years. Recent Q4 2025 earnings showed an 11.5% YoY revenue decline and a significant EPS drop, missing estimates. The Q1 2026 guidance projects negative EPS, and FY2026 guidance is substantially below consensus, indicating severe operational headwinds. The drastic cut in quarterly dividend from $0.58 to $0.08, coupled with 'elevated net leverage and fragile position,' signals significant financial stress. Analyst consensus is 'Reduce'. These factors, reinforcing the previous assessment, indicate no credible path to exponential growth and highlight substantial operational and financial risks, making 10x growth highly improbable.